Leerink Partners stays Outperform on Ovid Therapeutics Inc (OVID) following KCC2 R&D Day

April 15, 2026 11:16 AM

Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $5.00 price target on Ovid Therapeutics Inc (NASDAQ: OVID)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found